(WST) West Pharmaceutical - Overview
Sector: Healthcare | Industry: Medical Instruments & Supplies | Exchange: NYSE (USA) | Market Cap: 22.092m USD | Total Return: 50.6% in 12m
Avg Turnover: 214M
EPS Trend: -42.6%
Qual. Beats: 5
Rev. Trend: 72.5%
Qual. Beats: 1
Warnings
No concerns identified
Tailwinds
Supp Ema20, Idiosyncratic Leader, Confidence
West Pharmaceutical Services (WST) specializes in the design and production of containment and delivery systems for injectable medications. The company operates through two primary segments: Proprietary Products, which focuses on high-value components like stoppers, seals, and self-injection devices, and Contract-Manufactured Products, which provides assembly services for diagnostic and surgical tools. Founded in 1923, the firm maintains a global distribution network serving biologic, generic, and pharmaceutical manufacturers.
The company operates within the high-barrier healthcare supplies sector, where stringent regulatory requirements for drug purity and container closure integrity create significant moats for established incumbents. Its business model relies heavily on the razor-and-blade concept, as its specialized components are often integrated into the drugs regulatory filing, making them essential to the long-term lifecycle of the pharmaceutical product.
Investors can further examine the companys historical valuation and performance metrics by reviewing the data on ValueRay.
- High-value biologic drug packaging demand drives proprietary segment revenue growth
- GLP-1 weight loss drug expansion accelerates injectable component volume sales
- Destocking trends in global pharmaceutical inventories impact short-term organic sales
- Margin expansion depends on automated manufacturing efficiency and high-value product mix
- Regulatory compliance and sterilization quality standards influence long-term operational risk management
| Net Income: 542.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.11 > 0.02 and ΔFCF/TA 2.66 > 1.0 |
| NWC/Revenue: 35.80% < 20% (prev 32.15%; Δ 3.65% < -1%) |
| CFO/TA 0.17 > 3% & CFO 715.3m > Net Income 542.7m |
| Net Debt (-91.8m) to EBITDA (842.2m): -0.11 < 3 |
| Current Ratio: 2.71 > 1.5 & < 3 |
| Outstanding Shares: last quarter (72.4m) vs 12m ago -0.82% < -2% |
| Gross Margin: 36.24% > 18% (prev 34.66%; Δ 1.58% > 0.5%) |
| Asset Turnover: 83.34% > 50% (prev 80.03%; Δ 3.31% > 0%) |
| Interest Coverage Ratio: 89.95 > 6 (EBIT TTM 665.6m / Interest Expense TTM 7.40m) |
| A: 0.28 (Total Current Assets 1.83b - Total Current Liabilities 674.0m) / Total Assets 4.11b |
| B: 1.09 (Retained Earnings 4.48b / Total Assets 4.11b) |
| C: 0.17 (EBIT TTM 665.6m / Avg Total Assets 3.86b) |
| D: 2.67 (Book Value of Equity 2.99b / Total Liabilities 1.12b) |
| Altman-Z'' = 9.35 = AAA |
| DSRI: 1.13 (Receivables 685.6m/543.6m, Revenue 3.22b/2.90b) |
| GMI: 0.96 (GM 34.66% / 36.24%) |
| AQI: -2.17 (AQ_t -0.26 / AQ_t-1 0.12) |
| SGI: 1.11 (Revenue 3.22b / 2.90b) |
| TATA: -0.04 (NI 542.7m - CFO 715.3m) / TA 4.11b) |
| Beneish M = -4.76 (Cap -4..+1) = AAA |
As of June 05, 2026, the stock is trading at USD 317.32 with a total of 476,583 shares traded.
Over the past week, the price has changed by -1.39%,
over one month by +5.71%,
over three months by +27.62% and
over the past year by +50.58%.
West Pharmaceutical has received a consensus analysts rating of 4.69. Therefore, it is recommended to buy WST.
- StrongBuy: 10
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 349.9 | 10.3% |
P/E Trailing = 41.8621
P/E Forward = 36.3636
P/S = 6.8588
P/B = 7.3877
P/EG = 3.0086
Revenue TTM = 3.22b USD
EBIT TTM = 665.6m USD
EBITDA TTM = 842.2m USD
Long Term Debt = 202.8m USD (from longTermDebt, last quarter)
Short Term Debt = 21.4m USD (from shortTermDebt, last quarter)
Debt = 429.6m USD (from shortLongTermDebtTotal, last quarter) + Leases 113.4m
Net Debt = -91.8m USD (calculated: Debt 429.6m - CCE 521.4m)
Enterprise Value = 22.0b USD (22.1b + Debt 429.6m - CCE 521.4m)
Interest Coverage Ratio = 89.95 (Ebit TTM 665.6m / Interest Expense TTM 7.40m)
EV/FCF = 48.04x (Enterprise Value 22.0b / FCF TTM 458.0m)
FCF Yield = 2.08% (FCF TTM 458.0m / Enterprise Value 22.0b)
FCF Margin = 14.22% (FCF TTM 458.0m / Revenue TTM 3.22b)
Net Margin = 16.85% (Net Income TTM 542.7m / Revenue TTM 3.22b)
Gross Margin = 36.24% ((Revenue TTM 3.22b - Cost of Revenue TTM 2.05b) / Revenue TTM)
Gross Margin QoQ = 35.08% (prev 37.75%)
Tobins Q-Ratio = 5.35 (Enterprise Value 22.0b / Total Assets 4.11b)
Interest Expense / Debt = 1.72% (Interest Expense 7.40m / Debt 429.6m)
Taxrate = 20.87% (142.2m / 681.5m)
NOPAT = 526.7m (EBIT 665.6m * (1 - 20.87%))
Current Ratio = 2.71 (Total Current Assets 1.83b / Total Current Liabilities 674.0m)
Debt / Equity = 0.14 (Debt 429.6m / totalStockholderEquity, last quarter 2.99b)
Debt / EBITDA = -0.11 (Net Debt -91.8m / EBITDA 842.2m)
Debt / FCF = -0.20 (Net Debt -91.8m / FCF TTM 458.0m)
Total Stockholder Equity = 3.04b (last 4 quarters mean from totalStockholderEquity)
RoA = 14.05% (Net Income 542.7m / Total Assets 4.11b)
RoE = 17.87% (Net Income TTM 542.7m / Total Stockholder Equity 3.04b)
RoCE = 20.55% (EBIT 665.6m / Capital Employed (Equity 3.04b + L.T.Debt 202.8m))
RoIC = 15.98% (NOPAT 526.7m / Invested Capital 3.30b)
WACC = 6.84% (E(22.1b)/V(22.5b) * Re(6.95%) + D(429.6m)/V(22.5b) * Rd(1.72%) * (1-Tc(0.21)))
Discount Rate = 6.95% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -93.21 | Cagr: -1.56%
[DCF] Terminal Value 77.97% ; FCFF base≈397.6m ; Y1≈455.7m ; Y5≈670.7m
[DCF] Fair Price = 144.2 (EV 10.1b - Net Debt -91.8m = Equity 10.2b / Shares 70.6m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -42.58 | EPS CAGR: -3.43% | SUE: 2.49 | # QB: 5
Revenue Correlation: 72.54 | Revenue CAGR: 2.79% | SUE: 3.11 | # QB: 1
EPS current Quarter (2026-06-30): EPS=2.08 | Chg30d=+4.26% | Revisions=+73% | Analysts=11
EPS next Quarter (2026-09-30): EPS=2.13 | Chg30d=+1.84% | Revisions=+47% | Analysts=11
EPS current Year (2026-12-31): EPS=8.62 | Chg30d=+7.60% | Revisions=+79% | GrowthEPS=+18.2% | GrowthRev=+8.4%
EPS next Year (2027-12-31): EPS=9.55 | Chg30d=+7.45% | Revisions=+79% | GrowthEPS=+10.8% | GrowthRev=+6.2%
[Analyst] Revisions Ratio: +79%